Additional information, including the accepted abstracts, can be accessed on the EULAR 2025 Congress website. Presentation materials will be made available in the Science section under Scientific ...

STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the ...

STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the ...

Fate Therapeutics to present lupus treatment data at EULAR 2025 View all comments (0) 0 Latest comments Post Comment Guidelines Trade With A Regulated Broker Indices Commodities Bonds Stocks US 30 ...

STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the 11-14 ...

today announced two presentations at the upcoming European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is being held from June 11-14, 2025, at Fira de Barcelona in ...

Additional information, including the accepted abstracts, can be accessed on the EULAR 2025 Congress website. Presentation materials will be made available in the Science section under Scientific ...

SAN DIEGO - Fate Therapeutics Inc. (NASDAQ: FATE), a biopharmaceutical company currently valued at approximately $140 million, announced today that it will present clinical and preclinical data ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress.

today announced that clinical and preclinical data from the Company's off-the-shelf cell therapy product platform will be featured at the European Alliance of Associations for Rheumatology European ...